Company Quick10K Filing
ARYA Sciences Acquisition
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 -0 $-0
10-K 2020-03-06 Annual: 2019-12-31
10-Q 2019-11-13 Quarter: 2019-09-30
10-Q 2019-08-12 Quarter: 2019-06-30
10-Q 2019-05-13 Quarter: 2019-03-31
10-K 2019-03-25 Annual: 2018-12-31
S-1 2018-09-11 Public Filing
8-K 2020-03-18 Regulation FD, Other Events, Exhibits
8-K 2020-03-17 Enter Agreement, Regulation FD, Exhibits
8-K 2020-01-08

ARYA Sciences Acquisition Financials

ARYA Metrics, Comps, Filings

Annual | Quarterly

Business

While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we focus on industries that complement our management team's background, and in our search for targets for our initial business combination seek to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare related industries. In particular, we are targeting North American or European companies in the life sciences and medical technology sectors where our management has extensive investment experience. We may pursue a transaction in which our shareholders immediately prior to our initial business combination would collectively own a minority interest in the post-transaction company.

Our sponsor is an affiliate of Perceptive Advisors, a leading life sciences focused investment firm with over $5 billion of regulatory assets under management as of December 31, 2018. Since its launch in 1999, Perceptive Advisors has focused exclusively on the healthcare industry. Our founders are also the founder and management of Perceptive Advisors. Joseph Edelman, our Chairman, founded Perceptive Advisors in 1999. Adam Stone, our Chief Executive Officer, is the Chief Investment Officer of Perceptive Advisors, and Michael Altman, our Chief Financial Officer, is a senior analyst at Perceptive Advisors. Perceptive Advisors' investment activity is focused on identifying both private and public companies in the life sciences and medical technology sectors and currently has investments in over 150 companies. The team at Perceptive Advisors consists of trained scientists, physicians and financial analysts who are passionately committed to identifying innovation that can drive critical change to current treatment paradigms. Perceptive Advisors invests across the capital structure and throughout a company's growth cycle which provides access to a broad universe of management teams and companies seeking flexible capital solutions. Perceptive Advisors is also an active investor in pre-IPO financing rounds known as “crossovers.” Perceptive Advisors has invested in over 40 private companies since 2013 and in 2017 met with over 200 private companies in evaluation of private growth financing rounds, crossovers, and pre-IPO analysis.

While we may acquire a business in any industry, our focus is on the healthcare industry in the United States and other developed countries. We believe the healthcare industry, particularly the life sciences and medical technology sectors, represents an enormous and growing target market with a large number of potential target acquisition opportunities. Overall, total U.S. national health expenditures currently exceeds $3 trillion, and the Center for Medicare and Medicaid Services has estimated that total healthcare spending will approach 20% of total U.S. Gross Domestic Product over the coming years. According to IBISWorld, in 2017, the global biotechnology market represented approximately $328 billion in revenue and grew 5.3% per annum from 2012 to 2017.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Trinity Merger (TMCX) -0.1 0% 360,420 20,027 0 0 1,232 2,860 -149
Pure Acquisition (PACQ) -0.1 2% 424,521 414,168 0 0 7,008 9,390 -530
LF Capital Acquisition (LFAC) -0.2 1% 162,199 6,523 0 0 1,467 2,020 -331
Gores Holdings III (GRSH) -0.2 1% 408,618 16,470 0 0 3,167 4,667 -1,109
Priority Technology Holdings (PRTH) 0% 11.7 -7% 452,277 557,550 417,822 0 -30,094 39,013 456,819
Qiwi (QIWI) 0% 73,023,000 0 0 0 0 -2,500
Mudrick Capital Acquisition (MUDS) -0.1 1% 215,093 7,317 0 0 2,308 3,028 -267
Leo Holdings (LHC) 0.0 -1% 206,444 11,052 0 0 -1,274 -1,274 -0
Sentinel Energy Services (STNL) -0.1 1% 356,437 18,034 0 0 2,937 3,042 -180
Marchex (MCHX) 47% -21.0 -3% 119,117 23,729 77,541 36,590 -3,628 2,495 -52,467
Far Point Acquisition (FPAC) -0.1 1% 648,719 22,634 0 0 7,544 10,693 -1,056
Legacy Acquisition (LGC) -0.3 0% 307,699 12,005 0 0 1,533 2,588 -740
New Frontier (NFC) 0.3 -2% 296,780 15,879 0 0 -4,588 -4,588 -1,240
Twelve Seas Investment (TWLV) -0.0 1% 212,909 207,909 0 0 2,313 2,313 -43
ARYA Sciences Acquisition (ARYA) -0.4 1% 148,145 4,809 0 0 2,193 2,193 -963
Saban Capital Acquisition (SCACU) 0% -6.6 0% 216,527 16,356 2,801 0 0 7 -46
Regalwood Global Energy (RWGE) -0.1 1% 310,735 11,092 0 0 4,549 4,549 -370
Farfetch (FTCH) 0% 1,351,393 222,962 0 0 0 0 -49,935
Visa (V) 0% 0.4 17% 72,574,000 37,890,000 22,977,000 0 12,080,000 16,322,000 5,897,000
Collier Creek Holdings (CCH) -0.1 1% 450,085 15,928 0 0 6,442 6,442 -672

Balance Sheet ($'000)2018-12-31
Cash1,198
Accounts Receivable
Inventory
PP&E
Assets145,821
Accounts Payable
Long-Term Debt
Liabilities4,677
Stockholders' Equity5,000
Income Statement ($'000)2018-12-31
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A
Tax
Net Income
Cash Flow ($'000)2018-12-31
Cash Operating
Cash Investing
Cash Financing